CORE--CLINICAL BIOCHEMISTRY FACILITY

临床生化设施的目的是提供高质量的- 临床化学和生化流行病学对照分析 CCSG支持的AHF科学家。该设施的工作人员是一名设施负责人， John P.Richie，Jr.博士，实验室主管，Steven Colosimo，M.S. 临床化学家，Tara Bonanno，B.S.和临床协调员Julie 该设施的主要资源包括 强生Vitros 500大型机临床化学分析仪 几种便携式临床生化分析仪Dynatech 5000 96孔板 带有Biolinx软件的读卡器、闪烁计数器、HPLC、GC、 自动分析仪和自动血细胞分析仪。该设施提供 常规的临床化学分析和免疫分析以及专门的 使用退款机制的生物化学和生物标记物测试。在……里面 此外，该设施还参与了生物标记物的开发，用于 大规模的人体研究。这一设施为所有 CCSG支持的计划以及以编程方式一致的 在AHF和其他设施内的方案。大约10-15个对等- AHF资助的调查人员以及12-18名外部科学家利用 每年约6,000至10,000个样本 每年化验一次。在过去的一年里，该设施总使用量的63% 是由同行评审的NIH或ACS资助的项目。在目前的资金中 周期，我们计划扩大该设施的能力，以包括 血液学分析和人体研究正在进行，并计划在 以及支持AHFCC内正在进行的研究以及 以支持研究动物设施内正在进行的研究。在……里面 此外，为了协助实施人类调查，我们计划 提供临床协作和生物样本方面的专业知识 托收和银行业务。AHFCC内的这种新的专业知识是必不可少的 用于执行人体研究，特别是在内勒·达纳 需求明显增加的研究所。特别的 重要的是，该设施将提供保密协助 问题，特别是在涉及DNA分析的人体研究中。

The purpose of the Clinical Biochemistry Facility is to provide quality- controlled analyses for clinical chemistry and biochemical epidemiology to CCSG-supported AHF scientists. The facility is staffed by a facility head, John P. Richie, Jr., Ph.D. a lab supervisor, Steven Colosimo, M.S. a clinical chemist, Tara Bonanno, B.S. and a clinical coordinator, Julie Heidbrink-Fallon, B.A. The major resources of the facility include a Johnson & Johnson Vitros 500 Mainframe Clinical Chemistry Analyzer, several portable clinical chemistry analyzers Dynatech 5000 96 well plate reader with Biolinx software, scintillation counters, HPLCs, GC, autoanalyzers and a automate hematological analyzer. The facility offers routine clinical chemistry assays and immunoassays as well as specialized biochemistry and biomarker tests using a charge-back mechanism. In addition the facility is involved in biomarker development for use in large-scale human studies. This facility provides services to all of the CCSG-supported programs as well as to non-programmatically aligned programs within AHF and at other facilities. Approximately 10-15 peer- funded investigators at AHF as well as 12-18 external scientists make use of the facility each year for a total of about 6,000 to 10,000 samples assayed per year. Over the past year, 63% of the total use of the facility was by peer-reviewed NIH-or ACS-funded projects. In the present funding cycle, we plan to expand the capabilities of the facility to include hematological analyses and human studies underway and planned within the AHFCC as well as in support of ongoing studies within the AHFCC as well as in support of ongoing studies within the Research Animal Facility. In addition, to assist in the implementation of human investigation we plan to provide expertise in clinical coordination and biological sample collection and banking. This new expertise within the AHFCC is essential for the implementation of human studies, particularly at the Naylor Dana Institute where an increasing demand is clearly evident. Of particular importance, the facility will provide assistance with confidentiality issues especially in human studies involving DNA analysis.